{"name":"Abliva AB","slug":"abliva-ab","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"KL1333","genericName":"KL1333","slug":"kl1333","indication":"Treatment of various types of cancer, including glioblastoma and melanoma","status":"phase_2"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Midazolam injection","genericName":"Midazolam injection","slug":"midazolam-injection","indication":"Status Epilepticus","status":"marketed"}]}],"pipeline":[{"name":"KL1333","genericName":"KL1333","slug":"kl1333","phase":"phase_2","mechanism":"KL1333 is a small molecule that targets the mitochondrial permeability transition pore (mPTP) to induce cell death in cancer cells.","indications":["Treatment of various types of cancer, including glioblastoma and melanoma"],"catalyst":""},{"name":"Midazolam injection","genericName":"Midazolam injection","slug":"midazolam-injection","phase":"marketed","mechanism":"Small molecule","indications":["Status Epilepticus"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxPNHliZW56QVQ2V3pHRzZ3QWh1bzAxakltUFd1NUYyU3JTalVvay1rNXlfdTRMbnhTampNZlJSS3c0ajFESHZfXy0wWUtsbktWUDBGaUdQbmJIVHF0bkdIV3JmZGN4RDk5dXVmVGNsRGEwZ1U3blp5RWkxZEowems2TjRxTk1sQk91aTBaVV9LdFlHdGVHcXI5QTBzX19oNnRGLXNSeEwxbE1tSXY3RDlXb0dfMHQ?oc=5","date":"2025-09-18","type":"pipeline","source":"BioSpace","summary":"Neumirna Therapeutics Appoints Ellen K. Donnelly as Chief Executive Officer - BioSpace","headline":"Neumirna Therapeutics Appoints Ellen K. Donnelly as Chief Executive Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxQU0R4Ym44WGFjMndmWk9PZnFsZ3QzeWs2dEJxSGdZN1EyNjF4WGtvbmpYbW1mVXJfZ3dCUkNnUUdqTjBMSUprelh0WHEzR3g5cUVBcFQyZU1wZ01NTVEweTlFZmxjNFN2d21qb3dBdzBQYkhKcURoZWZuOVE1QkIyanlVZm5VR1N5djNOOWFPYTk5dGU1WDBXR3NZR1JEZHJoOVdTX2tlUW0tc29xSVBZWFg3M25HY0RFOUgw?oc=5","date":"2025-05-08","type":"earnings","source":"stocktitan.net","summary":"Pharming Group reports first quarter 2025 financial results and provides business update - stocktitan.net","headline":"Pharming Group reports first quarter 2025 financial results and provides business update","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxQLW5OSnk2THlQYkZ4X09nZEdsZG94cWZvT1dWWVh2UUtRcDU0QTdwbzQyZFBtb1pRMnd1ZnJCSUZZckRSTUZROFN5Wk84OHljbE5Da250ZERscGxmckhOcTZsQXM2RVpwOUlVQzYteHhocFQtTUxmY08xcm5vMnVvQllMX0ZVZHA5R2ZPdjdDd1NYcUZDc0ZLNnI3V3hlOFZiTzhaVi1nR0E0aENLTDhSZ0RyS0M?oc=5","date":"2024-12-16","type":"pipeline","source":"Fierce Biotech","summary":"Pharming pays $66M for Abliva and its 'blockbuster potential' mitochondrial disease med - Fierce Biotech","headline":"Pharming pays $66M for Abliva and its 'blockbuster potential' mitochondrial disease med","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2AFBVV95cUxQMHppSXd2RXNPOVdMN0Y2MndpNUk1SjFqTEFxSFVqanh4aEdRUzlpNzdra3RDS2kxT0hXRFhJMmNMUU5oR1ZWeGprUU9ZVjdCNGJFcmRXZXh0bWtGaF9Oc3d4MzgtcEV0RnRXdFIxUXU2RTByVTVzcWZ6SGtNNTdfS2xDYVBxUF82WGxFQ3dwSlhiNVZLcWNTVGJWNUxxc0hpUllVY3JaRmRjeXhUcTRVUlg0Z0l5MnBUUlY4OEN0TEdpVmhoei0wdF9Lc1JCVEQ2MFBPZDRZRG4?oc=5","date":"2024-12-15","type":"pipeline","source":"GlobeNewswire","summary":"Pharming announces public cash offer to the shareholders of Abliva AB - GlobeNewswire","headline":"Pharming announces public cash offer to the shareholders of Abliva AB","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE83ckZ1dFozLWlkenBXTmd1MG9PaUtyLXAwYjlEcC1wS240QlNUMHU2YXhENERpeUswcTY4M0NmQlE1M1NFWTZZRS15eUVRTWZyNjV4ZEJlaHhfVHMyRURRalBhS09JUEpLMG90aWhR?oc=5","date":"2023-09-06","type":"regulatory","source":"KED Global","summary":"Yungjin Pharm's new drug candidate gets Fast Track from FDA - KED Global","headline":"Yungjin Pharm's new drug candidate gets Fast Track from FDA","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxQQlN0Tk1xN2NRaTZ5aVc4ZG5lRUtYdzRMRnNDZkxsbTFQWUVMdkFEY040ZFZndjZZTTQyX3JQSE1XbzN6N0Q2T1lCc1owcEZMLWw3TjVRQTZPZW5HNzFHY1ZUXzlTczBrQi10Qkc5N2hnaDZLV1c1QnVZTmpsUHFiOUNRSGZ3SFlWZDB4aEJlZw?oc=5","date":"2021-08-20","type":"pipeline","source":"Biostock","summary":"NeuroVive Pharmaceutical changes name to Abliva - Biostock","headline":"NeuroVive Pharmaceutical changes name to Abliva","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxPTUdKYi16WlJHYnhXOWtyNU5UUGNPaXdVRUJVT3pmdWRaV3BnajMwajlGejAzbGttTm1xQWxPb1ltdzlNZDh1aG1DZkRIeUJkMnU3MTh6YlpDWVRFUmRtNmxYSHRhd0luT3lCbGJObm1QcGdlTnF3bDJCVnJpbHVYNE4tM2VZTzJ5REt1aUhKOTF2T0s4ODh3dmEtUnVLdGhMUk0zYnlLbw?oc=5","date":"2017-10-04","type":"pipeline","source":"Cision News","summary":"NeuroVive appoints Daniel Schale as Director of Communications - Cision News","headline":"NeuroVive appoints Daniel Schale as Director of Communications","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_2":1,"marketed":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}